Chemomab Therapeutics names new chief medical officer and vice president of Drug Development
15 November 2022 -

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), an Israel-based clinical-stage biotechnology company, announced on Monday that it has named Matthew Frankel, MD, MBA as its new chief medical officer (CMO) and vice president of Drug Development.

DrFrankel has held the position of vice president, Clinical Development and Medical Affairs, Specialty Pharma at Boehringer Ingelheim. He has served as vice president & head, Immunology and Dermatology Medical Unit at Novartis. He has served in clinical development leadership roles across geographies and therapeutic disease areas at Reata, Fibrogen, Abbotts Labs, and Schering Plough.

Dr Frankel holds a BA degree from Vassar College, an MD degree from the University of California School of Medicine, Los Angeles and an MBA from the J L Kellogg Graduate School of Management at Northwestern University.